BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business

Core Insights - Bausch Health, Inc. (BHC) shares increased by 11% following the announcement of the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. [1] - The acquisition allows Solta Medical, a subsidiary of Bausch Health, to take full control of its distribution in China, enhancing its market presence and operational efficiency [2][7] - The Chinese aesthetics market is rapidly growing, positioning Solta Medical to meet increasing demand for aesthetic treatments [3] Company Performance - Bausch Health reported better-than-expected third-quarter results for 2025, driven by its Salix and Solta businesses [4] - Solta Medical achieved revenues of $140 million, reflecting a 25% year-over-year increase, with a 24% organic growth primarily from the Asia Pacific region [8] - Despite recent gains, Bausch Health's shares have declined by 12.5% year-to-date, contrasting with the industry's growth of 23.7% [6] Financial Position - As of September 30, 2025, Bausch Health's long-term debt stood at $21 billion, with a cash balance of $1.3 billion [10]